Nine Diagnostics has been selected to join Creative Destruction Lab (CDL) — a highly selective, university-backed deep tech program founded at the University of Toronto Rotman School of Management. CDL is not a traditional accelerator. Companies advance by hitting rigorous technical and commercial milestones, working directly with top-tier investors, serial entrepreneurs, and domain experts — many of whom are active capital allocators who have built and exited companies at scale. Acceptance rates run at approximately 3–5%, spanning pre-seed through Series A companies across AI, biotech, quantum, and energy. CDL companies have collectively raised over $20B in equity capital and produced multiple unicorns, including Deep Genomics and Waabi. Selection places Nine Diagnostics within a globally recognized program with a proven track record of scaling science-driven companies into venture-backed category leaders — and puts us in direct proximity to the investors and partners who can help us get there. For Nine Diagnostics, this supports continued advancement of both our technical platform and commercialization strategy. Our approach — combining nanosensor arrays with machine learning to detect complex molecular patterns from small-volume samples — is designed to generalize across disease areas, with a particular focus on oncology and treatment response monitoring. CDL strengthens our ability to refine our roadmap, build strategic relationships, and advance toward clinical deployment at scale.
